Faeth Therapeutics, Inc. (FTH)
NASDAQ: FTH · Real-Time Price · USD
29.45
+1.16 (4.10%)
Jul 27, 2026, 1:17 PM EDT - Market open
Faeth Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 152.33 | 8.67 | 9.99 | 13.01 | 17.8 | 7.16 |
Short-Term Investments | 50.47 | 12.52 | 31.34 | 52.75 | 89.32 | 140.46 |
Cash & Short-Term Investments | 202.79 | 21.18 | 41.34 | 65.76 | 107.12 | 147.62 |
Cash Growth | 490.70% | -48.75% | -37.14% | -38.61% | -27.44% | 789.50% |
Other Current Assets | 1.44 | 0.32 | 0.59 | 1.49 | 1.47 | 0.92 |
Total Current Assets | 204.23 | 21.51 | 41.93 | 67.25 | 108.59 | 148.54 |
Net Property, Plant & Equipment | 0.98 | 1.38 | 3.38 | 7.04 | 9.72 | 4.64 |
Other Long-Term Assets | 0.17 | 0.02 | 0.05 | 0.09 | 0.06 | 0.04 |
Total Assets | 205.38 | 22.9 | 45.36 | 74.37 | 118.38 | 153.23 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accrued Expenses | 13.15 | 2.8 | 3.13 | 3.2 | 6.94 | 4.21 |
Current Portion of Leases | 1.04 | 1.45 | 2.32 | 2.44 | 2.13 | 0.68 |
Total Current Liabilities | 14.19 | 4.25 | 5.45 | 5.64 | 9.07 | 4.89 |
Long-Term Leases | - | 0.06 | 1.53 | 3.77 | 5.9 | 1.67 |
Other Long-Term Liabilities | 0 | - | - | 0.07 | - | 0.15 |
Total Long-Term Liabilities | 0 | 0.06 | 1.53 | 3.84 | 5.9 | 1.82 |
Total Liabilities | 14.19 | 4.31 | 6.98 | 9.48 | 14.97 | 6.71 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Preferred Stock | 328.48 | - | - | - | - | - |
Common Stock | - | - | - | 0 | 0 | 0 |
Additional Paid-in Capital | 316.11 | 301.73 | 300.45 | 297 | 302.2 | 296.05 |
Accumulated Other Comprehensive Income | -0.02 | 0 | -0.01 | -0.21 | -1 | -0.33 |
Retained Earnings | -453.37 | -283.14 | -262.05 | -231.9 | -197.79 | -149.21 |
Shareholders' Equity | -137.29 | 18.59 | 38.39 | 64.9 | 103.41 | 146.51 |
Total Liabilities & Equity | 205.38 | 22.9 | 45.36 | 74.37 | 118.38 | 153.23 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 1.04 | 1.51 | 3.85 | 6.21 | 8.03 | 2.35 |
Net Cash (Debt) | 201.75 | 19.68 | 37.49 | 59.55 | 99.08 | 145.27 |
Net Cash Growth | 548.25% | -47.52% | -37.04% | -39.90% | -31.79% | 813.00% |
Net Cash Per Share | 158.91 | 15.61 | 29.85 | 42.61 | 64.54 | 104.84 |
Book Value | -137.29 | 18.59 | 38.39 | 64.9 | 103.41 | 146.51 |
Book Value Per Share | -108.13 | 14.75 | 30.57 | 46.43 | 67.36 | 105.75 |
Tangible Book Value | -137.29 | 18.59 | 38.39 | 64.9 | 103.41 | 146.51 |
Tangible Book Value Per Share | -108.13 | 14.75 | 30.57 | 46.43 | 67.36 | 105.75 |